AZ R&D Boston Hosts U.S. Congresswoman Clark


Alisha Martin

11 March 2014

(Left to Right) Alice Pomponio, Head of North America Science Affairs, AstraZeneca; Carl Barrett, VP Translational Sciences, Oncology Innovative Medicines, AstraZeneca; Ambar Ahmed, Research Scientist, Oncology Innovative Medicines, AstraZeneca; Rep. Katherine Clark, U.S. House of Representatives; Jeff Brown, Director Translational Science Lead, Oncology Innovative Medicines, AstraZeneca; Melanie Frigault, Translational Science Strategist, Oncology Innovative Medicines, AstraZeneca; Jacqueline Kirby, VP US Government Affairs, AstraZeneca

On March 10, AstraZeneca leaders hosted U.S. Representative Katherine Clark at the company’s Boston Research and Development (R&D) site in Waltham, Mass. for an overview of the company’s discovery research and a tour of its laboratories.  The Waltham location – which employs hundreds of talented AstraZeneca researchers, scientists and support staff representing more than 30 nationalities – serves as the company’s headquarters for small-molecule discovery research in North America and global infectious disease research, with an additional significant focus on oncology drug research.

The tour featured opportunities for Rep. Clark to learn about AstraZeneca’s scientific discovery center, conduct of pharmacologic safety assessments, and the company’s research in oncology.

“It was a pleasure to visit with senior leaders and scientists at AstraZeneca’s Waltham R&D facility to learn about the cutting-edge research and strategic partnerships that are helping to advance science and further the discovery of new medicines.”

As part of the burgeoning Boston R&D community which boasts more than 450,000 healthcare and medical research employees, more than 400 biopharmaceutical companies and more than 53,000 biotech employees, AstraZeneca has forged a number of innovation collaborations with area organizations.  These include the Broad Institute, Massachusetts General Hospital, Harvard University, Massachusetts Institute of Technology (MIT), Tufts University, Moderna, X-Chem, Enlight Biosciences, Foundation Medicine, Cubist Pharmaceuticals and more.

Opened in 2000, AstraZeneca’s Waltham R&D complex has since expanded to more than 500,000 square feet, including 285,000 square feet of laboratory space.  In addition to this site, AstraZeneca has a manufacturing facility located in Westborough, Mass. and a neuroscience research team based in Cambridge, Mass.

(Left to Right) Prasad Nadella, Acting Head of Pathology, Global Safety Assessment, AstraZeneca; Rep. Katherine Clark, U.S. House of Representatives; Geoff Gallo, Director, U.S. State Government Affairs, AstraZeneca

AstraZeneca’s roots in Massachusetts extend much farther than the research community.  For decades, the company has provided qualified patients in the state with free medicine through its patient assistance programs, which include AZ&Me and the MedImmune Assistance Program.  In 2013 alone, these programs provided more than $1.3 million in savings to more than 760 patients in Massachusetts.

AstraZeneca’s commitment to Massachusetts is also reflected in its community partnerships and investments.  The AstraZeneca Hope Lodge, for example, arose from the company’s collaboration with the American Cancer Society and allows cancer patients and their family members to reside free of charge while they receive treatment for their illnesses in some of the world’s premier hospitals.